PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23200724-13 2013 In summary, CCK(B) signaling is involved in the regulation of food intake after a fast likely by downstream dopamine signaling. Dopamine 108-116 cholecystokinin Rattus norvegicus 12-15 22981453-3 2012 The physiological effect of CCK on cholinergic interneurons, which are the major interneurons in striatum and the modulatory interactions which exist between dopamine, acetylcholine and cholecystokinin in this brain structure are still unclear. Dopamine 158-166 cholecystokinin Rattus norvegicus 28-31 12560135-0 2003 Cholecystokinin combined with serotonin in the hypothalamus limits accumbens dopamine release while increasing acetylcholine: a possible satiation mechanism. Dopamine 77-85 cholecystokinin Rattus norvegicus 0-15 20680358-3 2010 First, injections of CCK-8 were found to induce c-fos mRNA expression in a vague patchy pattern that is different from single methamphetamine-induced Zebrin band-like c-fos mRNA expression, suggesting that the CCK-8 activating mossy fibers induce gene expression differently from the dopamine-containing mossy fibers in the ventral tegmental area. Dopamine 284-292 cholecystokinin Rattus norvegicus 21-24 20680358-3 2010 First, injections of CCK-8 were found to induce c-fos mRNA expression in a vague patchy pattern that is different from single methamphetamine-induced Zebrin band-like c-fos mRNA expression, suggesting that the CCK-8 activating mossy fibers induce gene expression differently from the dopamine-containing mossy fibers in the ventral tegmental area. Dopamine 284-292 cholecystokinin Rattus norvegicus 210-213 12932815-0 2003 Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats. Dopamine 22-30 cholecystokinin Rattus norvegicus 62-77 12932815-1 2003 The gut-brain peptide cholecystokinin (CCK) has been implicated in the regulation of dopamine (DA) transmission in the brain. Dopamine 85-93 cholecystokinin Rattus norvegicus 22-37 12932815-1 2003 The gut-brain peptide cholecystokinin (CCK) has been implicated in the regulation of dopamine (DA) transmission in the brain. Dopamine 85-93 cholecystokinin Rattus norvegicus 39-42 12932815-1 2003 The gut-brain peptide cholecystokinin (CCK) has been implicated in the regulation of dopamine (DA) transmission in the brain. Dopamine 95-97 cholecystokinin Rattus norvegicus 22-37 12932815-1 2003 The gut-brain peptide cholecystokinin (CCK) has been implicated in the regulation of dopamine (DA) transmission in the brain. Dopamine 95-97 cholecystokinin Rattus norvegicus 39-42 12801586-1 2003 The unique distribution of CCK and its receptors and its co-localization with dopamine makes it ideally situated to pay a role in dopamine-mediated reward and psychostimulant sensitization. Dopamine 130-138 cholecystokinin Rattus norvegicus 27-30 12801586-2 2003 A number of studies support the hypothesis that CCK acting through the CCK 1 and CCK 2 receptors is an endogenous modulator of dopamine neurotransmission. Dopamine 127-135 cholecystokinin Rattus norvegicus 48-51 12801586-2 2003 A number of studies support the hypothesis that CCK acting through the CCK 1 and CCK 2 receptors is an endogenous modulator of dopamine neurotransmission. Dopamine 127-135 cholecystokinin Rattus norvegicus 71-74 12801586-2 2003 A number of studies support the hypothesis that CCK acting through the CCK 1 and CCK 2 receptors is an endogenous modulator of dopamine neurotransmission. Dopamine 127-135 cholecystokinin Rattus norvegicus 71-74 20680358-9 2010 Thus, we conclude that repeated methamphetamine administration though dopamine selectively inhibits the c-fos mRNA expression after CCK-8 injection in the cerebellum. Dopamine 70-78 cholecystokinin Rattus norvegicus 132-135 15388290-2 2004 In the brain, CCK is colocalized and interacts with dopamine, respectively. Dopamine 52-60 cholecystokinin Rattus norvegicus 14-17 15388290-10 2004 Treatment with Boc-CCK-4 (40 microg/kg ip) did not affect performance in sham-lesioned rats but restored the learning curve in lesioned rats without increasing swimming speed indicating a better spatial learning in the dopamine-depleted rats. Dopamine 219-227 cholecystokinin Rattus norvegicus 19-22 14972658-2 2004 Cholecystokinin (CCK) is co-localized with dopamine (DA) in up to 90% of mesolimbic DA neurons. Dopamine 43-51 cholecystokinin Rattus norvegicus 0-15 14972658-2 2004 Cholecystokinin (CCK) is co-localized with dopamine (DA) in up to 90% of mesolimbic DA neurons. Dopamine 43-51 cholecystokinin Rattus norvegicus 17-20 14972658-2 2004 Cholecystokinin (CCK) is co-localized with dopamine (DA) in up to 90% of mesolimbic DA neurons. Dopamine 53-55 cholecystokinin Rattus norvegicus 0-15 12801586-1 2003 The unique distribution of CCK and its receptors and its co-localization with dopamine makes it ideally situated to pay a role in dopamine-mediated reward and psychostimulant sensitization. Dopamine 78-86 cholecystokinin Rattus norvegicus 27-30 12560135-7 2003 However, 5-HT plus CCK injected in combination decreased DA to 72% (P<0.001) and simultaneously increased extracellular ACh to 128% of baseline (P<0.001). Dopamine 57-59 cholecystokinin Rattus norvegicus 19-22 12065614-1 2002 Cholecystokinin (CCK) is co-localized with dopamine, is known to modulate dopamine neurotransmission and is involved in behavioral sensitization to psychostimulants. Dopamine 43-51 cholecystokinin Rattus norvegicus 0-15 12688383-1 2002 The distribution of some cholecystokinin (CCK) systems in the rat brain is reviewed focusing on mesencephalic dopamine neurones which coexpress CCK and, in particular, on cortico-striatal CCK neurones which probably have glutamate as their co-transmitter. Dopamine 110-118 cholecystokinin Rattus norvegicus 25-40 12688383-1 2002 The distribution of some cholecystokinin (CCK) systems in the rat brain is reviewed focusing on mesencephalic dopamine neurones which coexpress CCK and, in particular, on cortico-striatal CCK neurones which probably have glutamate as their co-transmitter. Dopamine 110-118 cholecystokinin Rattus norvegicus 42-45 12065614-1 2002 Cholecystokinin (CCK) is co-localized with dopamine, is known to modulate dopamine neurotransmission and is involved in behavioral sensitization to psychostimulants. Dopamine 43-51 cholecystokinin Rattus norvegicus 17-20 12065614-1 2002 Cholecystokinin (CCK) is co-localized with dopamine, is known to modulate dopamine neurotransmission and is involved in behavioral sensitization to psychostimulants. Dopamine 74-82 cholecystokinin Rattus norvegicus 0-15 12065614-1 2002 Cholecystokinin (CCK) is co-localized with dopamine, is known to modulate dopamine neurotransmission and is involved in behavioral sensitization to psychostimulants. Dopamine 74-82 cholecystokinin Rattus norvegicus 17-20 11999900-3 2002 The antipsychotic potential of cholecystokinin (CCK) stems from its colocalization with dopamine (DA) in the mesolimbic pathway, where it demonstrates both excitatory and inhibitory effects on dopaminergic activity. Dopamine 88-96 cholecystokinin Rattus norvegicus 31-46 12065614-9 2002 These results provide a neurochemical basis for an important role of CCK (via modulation of dopamine neurotransmission) in expression of cocaine sensitization. Dopamine 92-100 cholecystokinin Rattus norvegicus 69-72 11999900-3 2002 The antipsychotic potential of cholecystokinin (CCK) stems from its colocalization with dopamine (DA) in the mesolimbic pathway, where it demonstrates both excitatory and inhibitory effects on dopaminergic activity. Dopamine 88-96 cholecystokinin Rattus norvegicus 48-51 11999900-3 2002 The antipsychotic potential of cholecystokinin (CCK) stems from its colocalization with dopamine (DA) in the mesolimbic pathway, where it demonstrates both excitatory and inhibitory effects on dopaminergic activity. Dopamine 98-100 cholecystokinin Rattus norvegicus 31-46 11999900-3 2002 The antipsychotic potential of cholecystokinin (CCK) stems from its colocalization with dopamine (DA) in the mesolimbic pathway, where it demonstrates both excitatory and inhibitory effects on dopaminergic activity. Dopamine 98-100 cholecystokinin Rattus norvegicus 48-51 10683486-1 2000 The antipsychotic potential of cholecystokinin (CCK)-related compounds stems from CCK"s colocalization with dopamine (DA). Dopamine 108-116 cholecystokinin Rattus norvegicus 31-46 11754493-1 2002 Evidence suggests that endogenous cholecystokinin (CCK), a neuropeptide that modulates brain dopamine function, may contribute to the therapeutic and motor effects of antipsychotic drugs via activation of CCK-A receptors in the mesolimbic and nigrostriatal pathways, respectively. Dopamine 93-101 cholecystokinin Rattus norvegicus 34-49 11754493-1 2002 Evidence suggests that endogenous cholecystokinin (CCK), a neuropeptide that modulates brain dopamine function, may contribute to the therapeutic and motor effects of antipsychotic drugs via activation of CCK-A receptors in the mesolimbic and nigrostriatal pathways, respectively. Dopamine 93-101 cholecystokinin Rattus norvegicus 51-54 11754493-1 2002 Evidence suggests that endogenous cholecystokinin (CCK), a neuropeptide that modulates brain dopamine function, may contribute to the therapeutic and motor effects of antipsychotic drugs via activation of CCK-A receptors in the mesolimbic and nigrostriatal pathways, respectively. Dopamine 93-101 cholecystokinin Rattus norvegicus 205-208 11294486-5 2001 DA release from Acb was increased with increasing intensity or frequency of electrical stimulation in a dose-dependent manner and was inhibited by microinjection of CCK-8 (0.5 microg/kg) into the ventral tegmental area. Dopamine 0-2 cholecystokinin Rattus norvegicus 165-168 11294486-7 2001 The release of DA was clearly reduced at all the intensities (0.25, 0.5, 0.75 and 1.0 mA) tested following CCK injection into the VTA, which was statistically significant (P<0.05). Dopamine 15-17 cholecystokinin Rattus norvegicus 107-110 11020226-1 2000 Cholecystokinin octapeptide (CCK-8) coexists with dopamine (DA) in rat mesencephalic neurons that project to the nucleus accumbens. Dopamine 50-58 cholecystokinin Rattus norvegicus 0-15 10686405-1 2000 Converging evidence supports a role for cholecystokinin (CCK) in modulating dopamine (DA)-mediated activity in the rat mesolimbic system. Dopamine 76-84 cholecystokinin Rattus norvegicus 40-55 10686405-1 2000 Converging evidence supports a role for cholecystokinin (CCK) in modulating dopamine (DA)-mediated activity in the rat mesolimbic system. Dopamine 76-84 cholecystokinin Rattus norvegicus 57-60 10686405-1 2000 Converging evidence supports a role for cholecystokinin (CCK) in modulating dopamine (DA)-mediated activity in the rat mesolimbic system. Dopamine 86-88 cholecystokinin Rattus norvegicus 40-55 10686405-1 2000 Converging evidence supports a role for cholecystokinin (CCK) in modulating dopamine (DA)-mediated activity in the rat mesolimbic system. Dopamine 86-88 cholecystokinin Rattus norvegicus 57-60 10683486-1 2000 The antipsychotic potential of cholecystokinin (CCK)-related compounds stems from CCK"s colocalization with dopamine (DA). Dopamine 108-116 cholecystokinin Rattus norvegicus 48-51 10683486-1 2000 The antipsychotic potential of cholecystokinin (CCK)-related compounds stems from CCK"s colocalization with dopamine (DA). Dopamine 108-116 cholecystokinin Rattus norvegicus 82-85 10793220-0 2000 CCK/dopamine interactions in Fawn-Hooded and Wistar-Kyoto rat brain. Dopamine 4-12 cholecystokinin Rattus norvegicus 0-3 10683486-1 2000 The antipsychotic potential of cholecystokinin (CCK)-related compounds stems from CCK"s colocalization with dopamine (DA). Dopamine 118-120 cholecystokinin Rattus norvegicus 31-46 10683486-1 2000 The antipsychotic potential of cholecystokinin (CCK)-related compounds stems from CCK"s colocalization with dopamine (DA). Dopamine 118-120 cholecystokinin Rattus norvegicus 48-51 10683486-1 2000 The antipsychotic potential of cholecystokinin (CCK)-related compounds stems from CCK"s colocalization with dopamine (DA). Dopamine 118-120 cholecystokinin Rattus norvegicus 82-85 10683486-2 2000 CCK demonstrates excitatory and inhibitory effects on DA in the mesolimbic pathway. Dopamine 54-56 cholecystokinin Rattus norvegicus 0-3 10650159-10 2000 The results suggest a dual opposite mechanism for CCK-dopamine interactions. Dopamine 54-62 cholecystokinin Rattus norvegicus 50-53 9272833-1 1997 Cholecystokinin (CCK) is co-localized with dopamine (DA) in the nucleus accumbens (NAC) where evidence suggests that CCK(B) receptor-mediated mechanisms inhibit, while CCK(A) receptor-mediated mechanisms facilitate, DA function. Dopamine 43-51 cholecystokinin Rattus norvegicus 0-15 9639255-0 1998 Extracellular dopamine in the anterior nucleus accumbens is distinctly affected by ventral tegmental area administration of cholecystokinin and apomorphine: data from in vivo voltammetry. Dopamine 14-22 cholecystokinin Rattus norvegicus 124-139 9639255-4 1998 In agreement with an earlier study there was a dose-dependent increase in the DA signal in the anterior NA after microinjection of CCK-8s into the VTA. Dopamine 78-80 cholecystokinin Rattus norvegicus 131-134 9639255-8 1998 These results suggest that low doses of apomorphine injected into the VTA synergistically influence the effects of CCK-8s on extracellular DA in the anterior NA, whereas higher doses of apomorphine suppress the effect of CCK-8s on DAergic cells projecting to the anterior NA. Dopamine 139-141 cholecystokinin Rattus norvegicus 115-118 9586867-4 1998 The neuropeptide cholecystokinin (CCK), which coexists with dopamine (DA) in some brain regions, has been implicated in the pathophysiology of schizophrenia. Dopamine 60-68 cholecystokinin Rattus norvegicus 34-37 9586867-4 1998 The neuropeptide cholecystokinin (CCK), which coexists with dopamine (DA) in some brain regions, has been implicated in the pathophysiology of schizophrenia. Dopamine 70-72 cholecystokinin Rattus norvegicus 34-37 9517439-0 1997 The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: evidence for a novel CCK receptor subtype? Dopamine 24-32 cholecystokinin Rattus norvegicus 15-18 9517439-1 1997 The neuropeptide cholecystokinin (CCK) has been shown to interact with dopamine in various ways, including attenuation of dopamine D1 receptor-mediated vacuous chewing and grooming. Dopamine 71-79 cholecystokinin Rattus norvegicus 34-37 9517439-6 1997 The suppression of dopamine D1 agonist-induced grooming by CCK-4 does not appear to reflect a non-specific effect of anxiogenesis, as it was unaffected by the anxiolytic diazepam. Dopamine 19-27 cholecystokinin Rattus norvegicus 59-62 9272833-1 1997 Cholecystokinin (CCK) is co-localized with dopamine (DA) in the nucleus accumbens (NAC) where evidence suggests that CCK(B) receptor-mediated mechanisms inhibit, while CCK(A) receptor-mediated mechanisms facilitate, DA function. Dopamine 43-51 cholecystokinin Rattus norvegicus 17-20 9272833-1 1997 Cholecystokinin (CCK) is co-localized with dopamine (DA) in the nucleus accumbens (NAC) where evidence suggests that CCK(B) receptor-mediated mechanisms inhibit, while CCK(A) receptor-mediated mechanisms facilitate, DA function. Dopamine 53-55 cholecystokinin Rattus norvegicus 0-15 11224447-1 1996 Cholecystokinin (CCK) is co-localized with dopamine (DA) in portions of the mesolimbic system. Dopamine 43-51 cholecystokinin Rattus norvegicus 0-15 11224447-1 1996 Cholecystokinin (CCK) is co-localized with dopamine (DA) in portions of the mesolimbic system. Dopamine 43-51 cholecystokinin Rattus norvegicus 17-20 11224447-1 1996 Cholecystokinin (CCK) is co-localized with dopamine (DA) in portions of the mesolimbic system. Dopamine 53-55 cholecystokinin Rattus norvegicus 0-15 8884775-1 1996 The effect of cholecystokinin peptides on the release of dynorphin B, aspartate, glutamate, dopamine and GABA in the neostriatum and substantia nigra of the rat was investigated using in vivo microdialysis. Dopamine 92-100 cholecystokinin Rattus norvegicus 14-29 9181874-0 1996 [The effect of cholecystokinin octapeptide on ethanol-induced changes in motor activity and in dopamine metabolism in the nucleus accumbens of the rat brain]. Dopamine 95-103 cholecystokinin Rattus norvegicus 15-30 9181874-1 1996 The effect of intraventricular injection of cholecystokinin-octapeptide (CCK-8) in doses of 0.1875; 0.375; 0.75 and 1.5 micrograms/rat on the extracellular level of dopamine (DA) and its metabolites (DOPAC and HVA) after intraperitoneal injection of 1.5 g/kg ethanol was studied by microdialysis in n. accumbens of the brain of freely moving rats. Dopamine 165-173 cholecystokinin Rattus norvegicus 44-59 8884775-3 1996 Striatal dopamine levels were only increased by 100 microM of cholecystokinin-8S, while in the substantia nigra they were increased by 10-100 microM of cholecystokinin-8S. Dopamine 9-17 cholecystokinin Rattus norvegicus 62-77 8884775-13 1996 Pretreatment with L-364,718, but not with L-365.260, prevented the increase in nigral dopamine levels produced by nigral cholecystokinin-8S administration. Dopamine 86-94 cholecystokinin Rattus norvegicus 121-136 8884775-16 1996 Cholecystokinin-8S modulates dopamine release mainly in the substantia nigra, via the cholecystokinin-A receptor subtype. Dopamine 29-37 cholecystokinin Rattus norvegicus 0-15 7881050-1 1994 Sulphated cholecystokinin-8 (CCK-8) given into the neostriatum of the rat by in vivo microdialysis produced a concentration-dependent (1-100 microM) increase in extracellular aspartate (Asp) and dynorphin B (Dyn B), but not in glutamate, GABA or dopamine levels. Dopamine 246-254 cholecystokinin Rattus norvegicus 10-25 8867913-8 1996 We conclude that CCK can modify dopamine-mediated behavioural responses, possibly reflecting an action post-synaptic to dopamine terminals. Dopamine 32-40 cholecystokinin Rattus norvegicus 17-20 8867913-8 1996 We conclude that CCK can modify dopamine-mediated behavioural responses, possibly reflecting an action post-synaptic to dopamine terminals. Dopamine 120-128 cholecystokinin Rattus norvegicus 17-20 7583328-0 1995 Cholecystokinin-induced release of dopamine in the nucleus accumbens of the spontaneously hypertensive rat. Dopamine 35-43 cholecystokinin Rattus norvegicus 0-15 7583328-2 1995 This investigation tested the hypothesis that the sulfated octapeptide cholecystokinin (CCK8S) induced release of dopamine is greater in the SHR than in its normotensive control, the Wistar-Kyoto rat (WKY). Dopamine 114-122 cholecystokinin Rattus norvegicus 71-86 8542299-1 1995 The carboxyterminal octapeptide of cholecystokinin (CCK-8) coexists with dopamine (DA) in mesolimbic neurons of the ventral tegmental area (VTA). Dopamine 73-81 cholecystokinin Rattus norvegicus 35-50 8542299-1 1995 The carboxyterminal octapeptide of cholecystokinin (CCK-8) coexists with dopamine (DA) in mesolimbic neurons of the ventral tegmental area (VTA). Dopamine 73-81 cholecystokinin Rattus norvegicus 52-55 8542299-1 1995 The carboxyterminal octapeptide of cholecystokinin (CCK-8) coexists with dopamine (DA) in mesolimbic neurons of the ventral tegmental area (VTA). Dopamine 83-85 cholecystokinin Rattus norvegicus 35-50 7613631-4 1995 Ex vivo studies demonstrated that 30 min after an intraventricular injection of 1 nmol/rat CCK-8 the KD value of [3H]NPA binding sites in the caudal part of the forebrain and the IC50 value of dopamine for [125I]iodosulpride binding sites in the caudal part of the nucleus accumbens were significantly increased by 160% and decreased by 77% respectively. Dopamine 193-201 cholecystokinin Rattus norvegicus 91-94 7613631-6 1995 The present studies also provide evidence for stronger modulation of D2 receptors by CCK-8 in the area of CCK/dopamine coexistence in the nucleus accumbens than in other basal ganglion areas, supporting the existence of CCK/D2 receptor interactions in cotransmission. Dopamine 110-118 cholecystokinin Rattus norvegicus 85-88 7613631-6 1995 The present studies also provide evidence for stronger modulation of D2 receptors by CCK-8 in the area of CCK/dopamine coexistence in the nucleus accumbens than in other basal ganglion areas, supporting the existence of CCK/D2 receptor interactions in cotransmission. Dopamine 110-118 cholecystokinin Rattus norvegicus 106-109 7613631-6 1995 The present studies also provide evidence for stronger modulation of D2 receptors by CCK-8 in the area of CCK/dopamine coexistence in the nucleus accumbens than in other basal ganglion areas, supporting the existence of CCK/D2 receptor interactions in cotransmission. Dopamine 110-118 cholecystokinin Rattus norvegicus 106-109 7894334-6 1994 The results suggest that dopamine is co-stored with cholecystokinin in large dense vesicles in rat striatum. Dopamine 25-33 cholecystokinin Rattus norvegicus 52-67 8741936-1 1996 Cholecystokinin (CCK) is co-localized with dopamine (DA) in portions of the mesolimbic system, where it may facilitate the function of DA through the CCKA receptor subtype. Dopamine 43-51 cholecystokinin Rattus norvegicus 0-15 8741936-1 1996 Cholecystokinin (CCK) is co-localized with dopamine (DA) in portions of the mesolimbic system, where it may facilitate the function of DA through the CCKA receptor subtype. Dopamine 43-51 cholecystokinin Rattus norvegicus 17-20 8741936-1 1996 Cholecystokinin (CCK) is co-localized with dopamine (DA) in portions of the mesolimbic system, where it may facilitate the function of DA through the CCKA receptor subtype. Dopamine 53-55 cholecystokinin Rattus norvegicus 0-15 8584197-0 1995 Cholecystokinin [corrected] octapeptide modulates dopamine release in rat striatum. Dopamine 50-58 cholecystokinin Rattus norvegicus 0-15 8584197-3 1995 Field electrical stimulation (FES) (2 Hz) induced an increase of dopamine release from striatal slices, which was Ca2+ dependent and was abolished by tetrodotoxin, 10(-6) M. Cholecystokinin octapeptide (10(-9) M, 10(-8) M and 10(-7) M) dose dependently reduced the electrically evoked release of [3H]DA. Dopamine 65-73 cholecystokinin Rattus norvegicus 174-189 7613631-3 1995 In contrast, 1 nM CCK-8 significantly decreased the IC50 value of dopamine for binding sites for the D2 antagonist [125I]iodosulpride in the rostral and caudal parts of the caudate-putamen by 46 and 56% respectively, and in the rostral and caudal parts of the nucleus accumbens (areas of CCK-dopamine coexistence) by 57 and 75% respectively. Dopamine 66-74 cholecystokinin Rattus norvegicus 18-21 7613631-3 1995 In contrast, 1 nM CCK-8 significantly decreased the IC50 value of dopamine for binding sites for the D2 antagonist [125I]iodosulpride in the rostral and caudal parts of the caudate-putamen by 46 and 56% respectively, and in the rostral and caudal parts of the nucleus accumbens (areas of CCK-dopamine coexistence) by 57 and 75% respectively. Dopamine 66-74 cholecystokinin Rattus norvegicus 288-291 7613631-3 1995 In contrast, 1 nM CCK-8 significantly decreased the IC50 value of dopamine for binding sites for the D2 antagonist [125I]iodosulpride in the rostral and caudal parts of the caudate-putamen by 46 and 56% respectively, and in the rostral and caudal parts of the nucleus accumbens (areas of CCK-dopamine coexistence) by 57 and 75% respectively. Dopamine 292-300 cholecystokinin Rattus norvegicus 18-21 7867757-4 1994 We found that CCK potentiated MA-induced DA release in the anterior striatum. Dopamine 41-43 cholecystokinin Rattus norvegicus 14-17 7881050-1 1994 Sulphated cholecystokinin-8 (CCK-8) given into the neostriatum of the rat by in vivo microdialysis produced a concentration-dependent (1-100 microM) increase in extracellular aspartate (Asp) and dynorphin B (Dyn B), but not in glutamate, GABA or dopamine levels. Dopamine 246-254 cholecystokinin Rattus norvegicus 29-32 8487948-0 1993 Cholecystokinin-dependent regulation of host dopamine inputs to striatal grafts. Dopamine 45-53 cholecystokinin Rattus norvegicus 0-15 7912631-0 1994 Reversal of CRF- and dopamine-induced stimulation of colonic motility by CCK and igmesine (JO 1784) in the rat. Dopamine 21-29 cholecystokinin Rattus norvegicus 73-76 8026297-1 1994 Cholecystokinin (CCK) has been implicated as a modulator of dopamine (DA) neurotransmission in the mesolimbic DA pathway, a primary pathway implicated in the effects of cocaine related to its abuse. Dopamine 60-68 cholecystokinin Rattus norvegicus 0-15 8026297-1 1994 Cholecystokinin (CCK) has been implicated as a modulator of dopamine (DA) neurotransmission in the mesolimbic DA pathway, a primary pathway implicated in the effects of cocaine related to its abuse. Dopamine 60-68 cholecystokinin Rattus norvegicus 17-20 8026297-1 1994 Cholecystokinin (CCK) has been implicated as a modulator of dopamine (DA) neurotransmission in the mesolimbic DA pathway, a primary pathway implicated in the effects of cocaine related to its abuse. Dopamine 70-72 cholecystokinin Rattus norvegicus 0-15 8026297-1 1994 Cholecystokinin (CCK) has been implicated as a modulator of dopamine (DA) neurotransmission in the mesolimbic DA pathway, a primary pathway implicated in the effects of cocaine related to its abuse. Dopamine 70-72 cholecystokinin Rattus norvegicus 17-20 8357529-0 1993 Cholecystokinin-dopamine interactions within the nucleus accumbens in the control over behaviour by conditioned reinforcement. Dopamine 16-24 cholecystokinin Rattus norvegicus 0-15 8357529-1 1993 Cholecystokinin (CCK) is colocalised with dopamine in the postero-medial nucleus accumbens (NAS). Dopamine 42-50 cholecystokinin Rattus norvegicus 0-15 8357529-1 1993 Cholecystokinin (CCK) is colocalised with dopamine in the postero-medial nucleus accumbens (NAS). Dopamine 42-50 cholecystokinin Rattus norvegicus 17-20 8332255-1 1993 Interactions between dopamine and neurotensin or dopamine and cholecystokinin have been demonstrated in the basal ganglia. Dopamine 21-29 cholecystokinin Rattus norvegicus 62-77 8332255-1 1993 Interactions between dopamine and neurotensin or dopamine and cholecystokinin have been demonstrated in the basal ganglia. Dopamine 49-57 cholecystokinin Rattus norvegicus 62-77 7820607-0 1994 Systemic administration of CCK-8S, but not CCK-4, enhances dopamine turnover in the posterior nucleus accumbens: a microdialysis study in freely moving rats. Dopamine 59-67 cholecystokinin Rattus norvegicus 27-30 7820607-1 1994 The present study was carried out to examine the effects of peripheral administration of sulfatedcholecystokinin octapeptide (CCK-8S) on dopamine (DA) turnover in the posterior nucleus accumbens (PNAc) and the caudate-putamen (CP) in awake rats. Dopamine 137-145 cholecystokinin Rattus norvegicus 126-129 7820607-1 1994 The present study was carried out to examine the effects of peripheral administration of sulfatedcholecystokinin octapeptide (CCK-8S) on dopamine (DA) turnover in the posterior nucleus accumbens (PNAc) and the caudate-putamen (CP) in awake rats. Dopamine 147-149 cholecystokinin Rattus norvegicus 126-129 8513278-3 1993 The reported co-existence of CCK and dopamine in some meso-limbic neurons has led to speculation that the neuropeptide may interact with the catecholamine in neuropsychopathologies linked to dopamine dysfunctions, like schizophrenia. Dopamine 191-199 cholecystokinin Rattus norvegicus 29-32 8487948-1 1993 Intrastriatal infusions of cholecystokinin-8-sulphate in the rat exerts a dose-dependent inhibition of dopamine-release from nigrostriatal terminals in the neostriatum, as measured by push-pull perfusion. Dopamine 103-111 cholecystokinin Rattus norvegicus 27-42 8487948-2 1993 This effect is abolished by excitotoxic lesions of the neostriatum, which, along with behavioural, electrophysiological and receptor binding studies, suggests that cholecystokinin exerts its action indirectly on dopamine release via receptors located on intrinsic striatal neurons. Dopamine 212-220 cholecystokinin Rattus norvegicus 164-179 21554661-10 1992 Pretreatment with alpha-methyl-rho-tyrosine partially reversed the inhibitory effect of Cholecystokinin octapeptide on sucrose ingestion, enhanced the effect of amphetamine but did not affect that of apomorphine, a dopamine agonist. Dopamine 215-223 cholecystokinin Rattus norvegicus 88-103 21554661-11 1992 The results support the possibility that the inhibitory effect of Cholecystokinin octapeptide on consummatory ingestive behaviour, in part, is mediated via release of dopamine in the brain. Dopamine 167-175 cholecystokinin Rattus norvegicus 66-81 1436504-2 1992 In situ hybridization histochemistry was used to investigate the putative regulation of cholecystokinin messenger RNA expression by dopamine in the rat striatum. Dopamine 132-140 cholecystokinin Rattus norvegicus 88-103 1360636-1 1992 In order to study the control mechanism of cholecystokinin (CCK) contents of the rat brain mediated by pre-synaptic receptors in dopamine (DA) neurons, R(+) and S(-) compounds of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), which are selective pre-synaptic dopaminergic agents, were administered in rats at low and high doses. Dopamine 129-137 cholecystokinin Rattus norvegicus 43-58 1360636-1 1992 In order to study the control mechanism of cholecystokinin (CCK) contents of the rat brain mediated by pre-synaptic receptors in dopamine (DA) neurons, R(+) and S(-) compounds of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), which are selective pre-synaptic dopaminergic agents, were administered in rats at low and high doses. Dopamine 129-137 cholecystokinin Rattus norvegicus 60-63 1436504-4 1992 Dopamine depletion caused by a 6-hydroxydopamine injection in the medical forebrain bundle induced, two and four weeks after the injection, an increase of cholecystokinin messenger RNA expression in the ipsilateral striatum. Dopamine 0-8 cholecystokinin Rattus norvegicus 155-170 1360636-1 1992 In order to study the control mechanism of cholecystokinin (CCK) contents of the rat brain mediated by pre-synaptic receptors in dopamine (DA) neurons, R(+) and S(-) compounds of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), which are selective pre-synaptic dopaminergic agents, were administered in rats at low and high doses. Dopamine 139-141 cholecystokinin Rattus norvegicus 43-58 1360636-1 1992 In order to study the control mechanism of cholecystokinin (CCK) contents of the rat brain mediated by pre-synaptic receptors in dopamine (DA) neurons, R(+) and S(-) compounds of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), which are selective pre-synaptic dopaminergic agents, were administered in rats at low and high doses. Dopamine 139-141 cholecystokinin Rattus norvegicus 60-63 1882334-1 1991 Extracellular recording techniques were combined with antidromic stimulation to examine the effects of C-terminal cholecystokinin (CCK) fragments and CCK antagonists on the activity of identified mesoaccumbens dopamine (MADA) neurons in chloral hydrate-anesthetized rats. Dopamine 210-218 cholecystokinin Rattus norvegicus 103-129 1359571-1 1992 In a variety of in vivo and in vitro tests, cholecystokinin (CCK) has been shown to produce effects that would suggest a functional antagonism of dopamine. Dopamine 146-154 cholecystokinin Rattus norvegicus 44-59 1359571-1 1992 In a variety of in vivo and in vitro tests, cholecystokinin (CCK) has been shown to produce effects that would suggest a functional antagonism of dopamine. Dopamine 146-154 cholecystokinin Rattus norvegicus 61-64 1527584-0 1992 Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. Dopamine 91-99 cholecystokinin Rattus norvegicus 18-33 1527584-0 1992 Subtype-selective cholecystokinin receptor antagonists block cholecystokinin modulation of dopamine-mediated behaviors in the rat mesolimbic pathway. Dopamine 91-99 cholecystokinin Rattus norvegicus 61-76 1527584-2 1992 The CCK-A antagonist L-364,718 (10 ng) blocked CCK potentiation of dopamine-induced hyperlocomotion in the medial posterior nucleus accumbens. Dopamine 67-75 cholecystokinin Rattus norvegicus 4-7 1527584-2 1992 The CCK-A antagonist L-364,718 (10 ng) blocked CCK potentiation of dopamine-induced hyperlocomotion in the medial posterior nucleus accumbens. Dopamine 67-75 cholecystokinin Rattus norvegicus 47-50 1527584-3 1992 The CCK-B antagonist CI-988 (20 ng) blocked CCK inhibition of dopamine-induced hyperlocomotion in the anterior nucleus accumbens. Dopamine 62-70 cholecystokinin Rattus norvegicus 4-7 1527584-3 1992 The CCK-B antagonist CI-988 (20 ng) blocked CCK inhibition of dopamine-induced hyperlocomotion in the anterior nucleus accumbens. Dopamine 62-70 cholecystokinin Rattus norvegicus 44-47 1527584-4 1992 The CCK-B antagonists CI-988 (20 ng) and L-365,260 (10 ng) blocked CCK potentiation of dopamine-induced hypolocomotion in the ventral tegmental area. Dopamine 87-95 cholecystokinin Rattus norvegicus 4-7 1527584-4 1992 The CCK-B antagonists CI-988 (20 ng) and L-365,260 (10 ng) blocked CCK potentiation of dopamine-induced hypolocomotion in the ventral tegmental area. Dopamine 87-95 cholecystokinin Rattus norvegicus 67-70 1527584-5 1992 These data indicate a CCK-B pharmacology in the cell body and anterior terminal field, and a CCK-A pharmacology in the posterior terminal field, of the mesolimbic dopamine pathway. Dopamine 163-171 cholecystokinin Rattus norvegicus 93-96 1523160-1 1992 Subpopulations of dopamine (DA) neurons in the ventral mesencephalon have been reported to contain cholecystokinin (CCK) and neurotensin (NT), giving rise to DA, DA/NT, NT/CCK and DA/CCK/NT projections. Dopamine 18-26 cholecystokinin Rattus norvegicus 116-119 1523160-1 1992 Subpopulations of dopamine (DA) neurons in the ventral mesencephalon have been reported to contain cholecystokinin (CCK) and neurotensin (NT), giving rise to DA, DA/NT, NT/CCK and DA/CCK/NT projections. Dopamine 18-26 cholecystokinin Rattus norvegicus 172-175 1523160-1 1992 Subpopulations of dopamine (DA) neurons in the ventral mesencephalon have been reported to contain cholecystokinin (CCK) and neurotensin (NT), giving rise to DA, DA/NT, NT/CCK and DA/CCK/NT projections. Dopamine 18-26 cholecystokinin Rattus norvegicus 180-189 1523160-1 1992 Subpopulations of dopamine (DA) neurons in the ventral mesencephalon have been reported to contain cholecystokinin (CCK) and neurotensin (NT), giving rise to DA, DA/NT, NT/CCK and DA/CCK/NT projections. Dopamine 28-30 cholecystokinin Rattus norvegicus 116-119 1523160-1 1992 Subpopulations of dopamine (DA) neurons in the ventral mesencephalon have been reported to contain cholecystokinin (CCK) and neurotensin (NT), giving rise to DA, DA/NT, NT/CCK and DA/CCK/NT projections. Dopamine 28-30 cholecystokinin Rattus norvegicus 172-175 1523160-1 1992 Subpopulations of dopamine (DA) neurons in the ventral mesencephalon have been reported to contain cholecystokinin (CCK) and neurotensin (NT), giving rise to DA, DA/NT, NT/CCK and DA/CCK/NT projections. Dopamine 28-30 cholecystokinin Rattus norvegicus 180-189 1312208-1 1992 The nigrostriatal dopaminergic activity was pharmacologically changed to assess whether dopamine (DA) regulates cholecystokinin (CCK) mRNA steady state in rat striatum. Dopamine 98-100 cholecystokinin Rattus norvegicus 112-127 1312208-1 1992 The nigrostriatal dopaminergic activity was pharmacologically changed to assess whether dopamine (DA) regulates cholecystokinin (CCK) mRNA steady state in rat striatum. Dopamine 98-100 cholecystokinin Rattus norvegicus 129-132 1312208-2 1992 Cocaine and benztropine, two dopaminergic agonists known to induce DA release and to block its re-uptake, produced a time dependent increase in CCK mRNA content in rat striatum. Dopamine 67-69 cholecystokinin Rattus norvegicus 144-147 21554660-15 1992 Injection of Cholecystokinin octapeptide (5 mug) suppressed pellet and sucrose intake in a manner comparable to that of apomorphine, but induced no behavioural stereotypes and caused a gradual, rather than inverted U-shaped, increase in the concentration of dopamine in the cerebrospinal fluid that did not correlate with the effect on ingestive behaviour. Dopamine 258-266 cholecystokinin Rattus norvegicus 13-28 21554661-0 1992 Evidence that Release of Dopamine in the Brain is Involved in the Inhibitory Effect of Cholecystokinin Octapeptide on Ingestion of Intraorally Administered Sucrose in Male Rats. Dopamine 25-33 cholecystokinin Rattus norvegicus 87-102 21554661-1 1992 To study the possibility that release of dopamine in the brain mediates the inhibitory effect of Cholecystokinin octapeptide on ingestive behaviour, the effect of amphetamine on intake of pellets or an intraorally administered sucrose solution was compared with that of Cholecystokinin octapeptide. Dopamine 41-49 cholecystokinin Rattus norvegicus 97-112 1346163-1 1992 Studies were undertaken to examine the role of dopamine in the regulation of cholecystokinin (CCK) release in slices of the rat caudate-putamen (CP), a region where both neuroactive substances are abundant yet not extensively colocalized. Dopamine 47-55 cholecystokinin Rattus norvegicus 94-97 1346163-2 1992 It was found that dopamine, acting through a D1 dopamine receptor, is a major factor regulating CCK release in this tissue. Dopamine 18-26 cholecystokinin Rattus norvegicus 96-99 1346163-8 1992 These results suggest that dopamine, acting through D1 receptors, increases CCK release in CP, cortex and hippocampus. Dopamine 27-35 cholecystokinin Rattus norvegicus 76-79 1346163-9 1992 The results of previous studies showing that phorbol esters increase CCK release and that occupation of D1 receptors increases phosphoinositol turnover make it possible to hypothesize that dopamine, acting through D1 receptors, is increasing CCK release by increasing phosphoinositol turnover. Dopamine 189-197 cholecystokinin Rattus norvegicus 69-72 1346163-9 1992 The results of previous studies showing that phorbol esters increase CCK release and that occupation of D1 receptors increases phosphoinositol turnover make it possible to hypothesize that dopamine, acting through D1 receptors, is increasing CCK release by increasing phosphoinositol turnover. Dopamine 189-197 cholecystokinin Rattus norvegicus 242-245 1346163-10 1992 Further studies will be required to verify this hypothesis and to determine whether dopamine is acting directly or indirectly to modulate CCK release. Dopamine 84-92 cholecystokinin Rattus norvegicus 138-141 1687681-2 1991 In an effort to evaluate CCK antagonists as potential antipsychotic drugs, we have examined the effects of a selective CCK-B antagonist, LY262691, on the number of spontaneously active midbrain dopamine neurons using extracellular, single-unit recordings in anesthetized rats. Dopamine 194-202 cholecystokinin Rattus norvegicus 119-122 19215497-0 1991 Involvement of dopamine in inhibition of food intake by cholecystokinin octapeptide in male rats. Dopamine 15-23 cholecystokinin Rattus norvegicus 56-71 19215497-1 1991 Abstract Deprivation of food reduced the level of dopamine in the cerebrospinal fluid of male rats and subsequent ingestion of food or intraperitoneal injection of Cholecystokinin octapeptide restored the level. Dopamine 50-58 cholecystokinin Rattus norvegicus 164-179 1681991-1 1991 The interaction of the cholecystokinin octapeptide (CCK-8) with dopamine (DA) and dopamine agonists on neurons in the nucleus accumbens was investigated using single unit recording and iontophoretic techniques in urethane-anaesthetized rats. Dopamine 64-72 cholecystokinin Rattus norvegicus 52-55 1681991-1 1991 The interaction of the cholecystokinin octapeptide (CCK-8) with dopamine (DA) and dopamine agonists on neurons in the nucleus accumbens was investigated using single unit recording and iontophoretic techniques in urethane-anaesthetized rats. Dopamine 74-76 cholecystokinin Rattus norvegicus 52-55 1681991-1 1991 The interaction of the cholecystokinin octapeptide (CCK-8) with dopamine (DA) and dopamine agonists on neurons in the nucleus accumbens was investigated using single unit recording and iontophoretic techniques in urethane-anaesthetized rats. Dopamine 82-90 cholecystokinin Rattus norvegicus 52-55 1681991-5 1991 The iontophoretic application of CCK reduced these attenuating effects of DA, LY 171555 and SKF 38393 + LY 171555. Dopamine 74-76 cholecystokinin Rattus norvegicus 33-36 1681991-7 1991 These observations provide additional electrophysiological evidence of the interaction of CCK and dopamine and suggest that the interaction is associated mainly with dopamine D2 mechanisms. Dopamine 98-106 cholecystokinin Rattus norvegicus 90-93 1882334-1 1991 Extracellular recording techniques were combined with antidromic stimulation to examine the effects of C-terminal cholecystokinin (CCK) fragments and CCK antagonists on the activity of identified mesoaccumbens dopamine (MADA) neurons in chloral hydrate-anesthetized rats. Dopamine 210-218 cholecystokinin Rattus norvegicus 131-134 1882334-1 1991 Extracellular recording techniques were combined with antidromic stimulation to examine the effects of C-terminal cholecystokinin (CCK) fragments and CCK antagonists on the activity of identified mesoaccumbens dopamine (MADA) neurons in chloral hydrate-anesthetized rats. Dopamine 210-218 cholecystokinin Rattus norvegicus 150-153 1993898-0 1991 Cholecystokinin modulates the release of dopamine from the anterior and posterior nucleus accumbens by two different mechanisms. Dopamine 41-49 cholecystokinin Rattus norvegicus 0-15 1993898-4 1991 In the anterior nucleus accumbens CCK sulphated octapeptide (1 microM) and CCK unsulphated octapeptide (0.1-1 microM) inhibited the dopamine release, and this effect was blocked by L365,260 (10-100 nM) but not by L364,718. Dopamine 132-140 cholecystokinin Rattus norvegicus 34-37 1993898-4 1991 In the anterior nucleus accumbens CCK sulphated octapeptide (1 microM) and CCK unsulphated octapeptide (0.1-1 microM) inhibited the dopamine release, and this effect was blocked by L365,260 (10-100 nM) but not by L364,718. Dopamine 132-140 cholecystokinin Rattus norvegicus 75-78 1993898-5 1991 These results suggest that CCK has a different effect on dopamine release from the anterior and posterior nucleus accumbens and that these effects are mediated by two different types of CCK receptor. Dopamine 57-65 cholecystokinin Rattus norvegicus 27-30 2611663-5 1989 Extracellular dopamine depletion using alpha-methyl-p-tyrosine or reserpine also increased the dialysate content of CCK-like immunoreactivity. Dopamine 14-22 cholecystokinin Rattus norvegicus 116-119 2029612-2 1991 The demonstration that cholecystokinin (CCK) co-exists and appears to be co-released with dopamine in the accumbens suggests that the modulatory action of dopamine in the accumbens may in turn be modified by CCK. Dopamine 90-98 cholecystokinin Rattus norvegicus 40-43 2029612-2 1991 The demonstration that cholecystokinin (CCK) co-exists and appears to be co-released with dopamine in the accumbens suggests that the modulatory action of dopamine in the accumbens may in turn be modified by CCK. Dopamine 155-163 cholecystokinin Rattus norvegicus 23-38 2029612-2 1991 The demonstration that cholecystokinin (CCK) co-exists and appears to be co-released with dopamine in the accumbens suggests that the modulatory action of dopamine in the accumbens may in turn be modified by CCK. Dopamine 155-163 cholecystokinin Rattus norvegicus 40-43 2029612-2 1991 The demonstration that cholecystokinin (CCK) co-exists and appears to be co-released with dopamine in the accumbens suggests that the modulatory action of dopamine in the accumbens may in turn be modified by CCK. Dopamine 155-163 cholecystokinin Rattus norvegicus 208-211 2029612-7 1991 Exogenous dopamine produced a similar attenuation in response and the attenuation was in turn suppressed by concurrent iontophoresis of sulphated CCK fragments applied at a current titrated not to produce significant effect on the spontaneous activity of the neurone nor its response to amygdala stimulation. Dopamine 10-18 cholecystokinin Rattus norvegicus 146-149 2029612-8 1991 These results demonstrate that exogenous and endogenous CCK can modify the postsynaptic action of dopamine in the nucleus accumbens in addition to modulating its release shown in other studies, and further suggests that CCK is likely an endogenous functional antagonist of dopamine, serving a comodulatory role in regulating synaptic transmission in the ventral striatum. Dopamine 98-106 cholecystokinin Rattus norvegicus 56-59 2029612-8 1991 These results demonstrate that exogenous and endogenous CCK can modify the postsynaptic action of dopamine in the nucleus accumbens in addition to modulating its release shown in other studies, and further suggests that CCK is likely an endogenous functional antagonist of dopamine, serving a comodulatory role in regulating synaptic transmission in the ventral striatum. Dopamine 98-106 cholecystokinin Rattus norvegicus 220-223 2029612-8 1991 These results demonstrate that exogenous and endogenous CCK can modify the postsynaptic action of dopamine in the nucleus accumbens in addition to modulating its release shown in other studies, and further suggests that CCK is likely an endogenous functional antagonist of dopamine, serving a comodulatory role in regulating synaptic transmission in the ventral striatum. Dopamine 273-281 cholecystokinin Rattus norvegicus 56-59 2029612-8 1991 These results demonstrate that exogenous and endogenous CCK can modify the postsynaptic action of dopamine in the nucleus accumbens in addition to modulating its release shown in other studies, and further suggests that CCK is likely an endogenous functional antagonist of dopamine, serving a comodulatory role in regulating synaptic transmission in the ventral striatum. Dopamine 273-281 cholecystokinin Rattus norvegicus 220-223 2113658-0 1990 Effect of dopamine depletion upon the K(+)-evoked release of CCK from superfused striatal slices. Dopamine 10-18 cholecystokinin Rattus norvegicus 61-64 2113658-1 1990 The effect of a lack of dopamine (DA) in the striatum upon the K(+)-evoked release of cholecystokinin (CCK) from superfused rat striatal slices has been studied. Dopamine 34-36 cholecystokinin Rattus norvegicus 86-101 2113658-1 1990 The effect of a lack of dopamine (DA) in the striatum upon the K(+)-evoked release of cholecystokinin (CCK) from superfused rat striatal slices has been studied. Dopamine 34-36 cholecystokinin Rattus norvegicus 103-106 2611663-7 1989 These data demonstrate that CCK-like immunoreactivity may be released from neuronal elements within the striatum by depolarizing stimuli in vivo, and suggest that increased overflow of CCK-like immunoreactivity is associated with dopamine depletion. Dopamine 230-238 cholecystokinin Rattus norvegicus 28-31 2611663-7 1989 These data demonstrate that CCK-like immunoreactivity may be released from neuronal elements within the striatum by depolarizing stimuli in vivo, and suggest that increased overflow of CCK-like immunoreactivity is associated with dopamine depletion. Dopamine 230-238 cholecystokinin Rattus norvegicus 185-188 2804664-0 1989 The effects of cholecystokinin (CCK-8) on dopamine-containing nerve terminals in the caudate nucleus and nucleus accumbens of the anesthetized rat: an in vivo electrochemical study. Dopamine 42-50 cholecystokinin Rattus norvegicus 32-35 2804664-4 1989 However, locally applied CCK-8S potentiated the potassium-evoked overflow of dopamine (DA) into the extracellular space in both the caudate and nucleus accumbens. Dopamine 77-85 cholecystokinin Rattus norvegicus 25-28 2804664-4 1989 However, locally applied CCK-8S potentiated the potassium-evoked overflow of dopamine (DA) into the extracellular space in both the caudate and nucleus accumbens. Dopamine 87-89 cholecystokinin Rattus norvegicus 25-28 2804664-6 1989 These data support a facilitatory effect of CCK-8S on potassium-evoked overflow from DA-containing nerve terminals in the urethane anesthetized rat that is likely mediated through a peripheral type CCK receptor. Dopamine 85-87 cholecystokinin Rattus norvegicus 44-47 2804664-6 1989 These data support a facilitatory effect of CCK-8S on potassium-evoked overflow from DA-containing nerve terminals in the urethane anesthetized rat that is likely mediated through a peripheral type CCK receptor. Dopamine 85-87 cholecystokinin Rattus norvegicus 198-201 2564343-7 1989 These results confirm recent double-labeling immunocytochemical studies and further characterize the coexistence of CCK and TH at the level of their mRNAs as well as their post-translational products in a large population of mesencephalic dopamine neurons known to project to forebrain areas. Dopamine 239-247 cholecystokinin Rattus norvegicus 116-119 2760604-4 1989 These findings suggest that dopamine (DA) neurons in these two regions are functionally related to intrinsic CCK-containing cortical neurons, and that CCK subsensitivity, perhaps due to an alteration in DA transmission, is involved in MAP sensitization. Dopamine 28-36 cholecystokinin Rattus norvegicus 109-112 2760604-4 1989 These findings suggest that dopamine (DA) neurons in these two regions are functionally related to intrinsic CCK-containing cortical neurons, and that CCK subsensitivity, perhaps due to an alteration in DA transmission, is involved in MAP sensitization. Dopamine 38-40 cholecystokinin Rattus norvegicus 109-112 2574480-15 1989 These results provide further evidence that CCK-8 modulates mesolimbic DA activity by functionally opposing the postsynaptic effects of DA in the region of the nucleus accumbens. Dopamine 71-73 cholecystokinin Rattus norvegicus 44-47 2466220-0 1989 Pharmacological and mechanistic studies of cholecystokinin-facilitated [3H]dopamine efflux from rat nucleus accumbens. Dopamine 75-83 cholecystokinin Rattus norvegicus 43-58 2466220-1 1989 Cholecystokinin (CCK) is co-localized with dopamine (DA) in mesolimbic neurons of the CNS and appears to selectively regulate the output of this system. Dopamine 43-51 cholecystokinin Rattus norvegicus 0-15 2466220-1 1989 Cholecystokinin (CCK) is co-localized with dopamine (DA) in mesolimbic neurons of the CNS and appears to selectively regulate the output of this system. Dopamine 43-51 cholecystokinin Rattus norvegicus 17-20 2466220-1 1989 Cholecystokinin (CCK) is co-localized with dopamine (DA) in mesolimbic neurons of the CNS and appears to selectively regulate the output of this system. Dopamine 53-55 cholecystokinin Rattus norvegicus 0-15 2740993-0 1989 Microinjection of cholecystokinin into the rat ventral tegmental area potentiates dopamine-induced hypolocomotion. Dopamine 82-90 cholecystokinin Rattus norvegicus 18-33 2740993-1 1989 Cholecystokinin, (CCK) 1-400 ng, significantly potentiated the hypolocomotion induced by dopamine, when simultaneously microinjected bilaterally into the ventral tegmental area (VTA) of rat brain. Dopamine 89-97 cholecystokinin Rattus norvegicus 0-24 2740993-4 1989 Pharmacological analysis indicated that both unsulfated CCK octapeptide (100 ng) and the C-terminal tetrapeptide of CCK (400 ng) potentiated dopamine-induced hypolocomotion in a manner identical with sulfated CCK octapeptide (100 ng). Dopamine 141-149 cholecystokinin Rattus norvegicus 56-59 2740993-4 1989 Pharmacological analysis indicated that both unsulfated CCK octapeptide (100 ng) and the C-terminal tetrapeptide of CCK (400 ng) potentiated dopamine-induced hypolocomotion in a manner identical with sulfated CCK octapeptide (100 ng). Dopamine 141-149 cholecystokinin Rattus norvegicus 116-119 2740993-4 1989 Pharmacological analysis indicated that both unsulfated CCK octapeptide (100 ng) and the C-terminal tetrapeptide of CCK (400 ng) potentiated dopamine-induced hypolocomotion in a manner identical with sulfated CCK octapeptide (100 ng). Dopamine 141-149 cholecystokinin Rattus norvegicus 116-119 2740993-7 1989 These findings suggest that CCK acts as a facilitatory modulator of dopamine at a central-type CCK receptor on the A10 cell bodies. Dopamine 68-76 cholecystokinin Rattus norvegicus 28-31 2740993-7 1989 These findings suggest that CCK acts as a facilitatory modulator of dopamine at a central-type CCK receptor on the A10 cell bodies. Dopamine 68-76 cholecystokinin Rattus norvegicus 95-98 3174761-1 1988 Cholecystokinin-octapeptide (CCK-8) has recently been found to coexist with dopamine (DA) in a subpopulation of midbrain DA neurons. Dopamine 76-84 cholecystokinin Rattus norvegicus 29-32 3392031-0 1988 A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum. Dopamine 105-113 cholecystokinin Rattus norvegicus 33-48 3392031-0 1988 A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum. Dopamine 105-113 cholecystokinin Rattus norvegicus 130-145 3392031-2 1988 Here, we describe experiments which demonstrate that a synthetic pseudopeptide analogue of CCK-7 is a potent agonist in the peripheral system and behaves as a selective and highly potent inhibitor of the dopamine-like effects of CCK in the striatum. Dopamine 204-212 cholecystokinin Rattus norvegicus 91-94 3392031-2 1988 Here, we describe experiments which demonstrate that a synthetic pseudopeptide analogue of CCK-7 is a potent agonist in the peripheral system and behaves as a selective and highly potent inhibitor of the dopamine-like effects of CCK in the striatum. Dopamine 204-212 cholecystokinin Rattus norvegicus 229-232 3077312-9 1988 Special attention was focused on CCK-LI in mesencephalic dopamine neurons and in their projection areas including nucleus accumbens, tuberculum olfactorium and particularly the caudate nucleus. Dopamine 57-65 cholecystokinin Rattus norvegicus 33-36 3427413-0 1987 Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro. Dopamine 28-36 cholecystokinin Rattus norvegicus 0-15 2903570-6 1988 The 6-OHDA lesion enhanced responsiveness of accumbens neurons to KA, GLU and CCK (the responsiveness to this latter peptide being increased by more than 15-fold) and the depressant effect of DA when applied during neuronal activation by KA or GLU but not when the same neurons were activated with CCK. Dopamine 8-10 cholecystokinin Rattus norvegicus 78-81 2903570-6 1988 The 6-OHDA lesion enhanced responsiveness of accumbens neurons to KA, GLU and CCK (the responsiveness to this latter peptide being increased by more than 15-fold) and the depressant effect of DA when applied during neuronal activation by KA or GLU but not when the same neurons were activated with CCK. Dopamine 8-10 cholecystokinin Rattus norvegicus 298-301 3427413-10 1987 These results suggest that co-localized CCK-S may significantly affect neuronal sensitivity to synaptically released DA. Dopamine 117-119 cholecystokinin Rattus norvegicus 40-43 3427413-0 1987 Cholecystokinin potentiates dopamine inhibition of mesencephalic dopamine neurons in vitro. Dopamine 65-73 cholecystokinin Rattus norvegicus 0-15 3427413-1 1987 Cholecystokinin octapeptide sulfate (CCK-S) is a neuropeptide that is co-localized with dopamine (DA) in some neurons of the ventral tegmental area (VTA). Dopamine 88-96 cholecystokinin Rattus norvegicus 0-15 3427413-1 1987 Cholecystokinin octapeptide sulfate (CCK-S) is a neuropeptide that is co-localized with dopamine (DA) in some neurons of the ventral tegmental area (VTA). Dopamine 88-96 cholecystokinin Rattus norvegicus 37-40 3427413-1 1987 Cholecystokinin octapeptide sulfate (CCK-S) is a neuropeptide that is co-localized with dopamine (DA) in some neurons of the ventral tegmental area (VTA). Dopamine 98-100 cholecystokinin Rattus norvegicus 0-15 3427413-1 1987 Cholecystokinin octapeptide sulfate (CCK-S) is a neuropeptide that is co-localized with dopamine (DA) in some neurons of the ventral tegmental area (VTA). Dopamine 98-100 cholecystokinin Rattus norvegicus 37-40 3427413-2 1987 A functional role for this peptide/monoamine co-localization has not been firmly established; however, behavioral and in vivo electrophysiological studies indicate that CCK-S modifies the action of DA in some brain areas. Dopamine 198-200 cholecystokinin Rattus norvegicus 169-172 3427413-8 1987 Prior administration of CCK-S to these cells markedly potentiated DA-induced inhibition of spontaneous firing; the magnitude of this effect ranged from a 24 to 376% increase in the inhibitory response. Dopamine 66-68 cholecystokinin Rattus norvegicus 24-27 3683774-0 1987 The chronic administration of dopamine antagonists and methamphetamine changed the [3H]-cholecystokinin-8 binding sites in the rat frontal cortex. Dopamine 30-38 cholecystokinin Rattus norvegicus 88-103 3441450-5 1987 In addition, the contraversive circling bias induced by CCK8 (5.0 ng, ICV) was attenuated by co-injections of the CCK antagonist proglumide (10 and 100 ng) and by intraperitoneal injections of the dopamine (DA) antagonist haloperidol (0.05 and 0.1 mg/kg, 45 min prior to ICV CCK8). Dopamine 197-205 cholecystokinin Rattus norvegicus 56-59 3441450-5 1987 In addition, the contraversive circling bias induced by CCK8 (5.0 ng, ICV) was attenuated by co-injections of the CCK antagonist proglumide (10 and 100 ng) and by intraperitoneal injections of the dopamine (DA) antagonist haloperidol (0.05 and 0.1 mg/kg, 45 min prior to ICV CCK8). Dopamine 207-209 cholecystokinin Rattus norvegicus 56-59 3683774-3 1987 The chronic administration of dopamine (DA) antagonists and methamphetamine (MAP) showed a tendency to increase the [3H]-CCK-8 binding sites (Bmax) in the frontal cortex. Dopamine 30-38 cholecystokinin Rattus norvegicus 121-124 3683774-3 1987 The chronic administration of dopamine (DA) antagonists and methamphetamine (MAP) showed a tendency to increase the [3H]-CCK-8 binding sites (Bmax) in the frontal cortex. Dopamine 40-42 cholecystokinin Rattus norvegicus 121-124 3683774-4 1987 Long-term treatments with DA antagonists led to the depletion of CCK-8 and may have caused an observed proliferation of CCK-8 receptors in the frontal cortex. Dopamine 26-28 cholecystokinin Rattus norvegicus 65-68 3683774-4 1987 Long-term treatments with DA antagonists led to the depletion of CCK-8 and may have caused an observed proliferation of CCK-8 receptors in the frontal cortex. Dopamine 26-28 cholecystokinin Rattus norvegicus 120-123 2884011-3 1987 Previous studies on the release of CCK from cp have focused on the influence of dopamine agonists. Dopamine 80-88 cholecystokinin Rattus norvegicus 35-38 3666030-1 1987 Systemic administration of the active, sulfated form of cholecystokinin-octapeptide (CCK-8S), at a dose known to inhibit dopamine (DA) release, significantly reduced the latency to ejaculate and number of intromissions preceding ejaculation in sexually active male rats. Dopamine 121-129 cholecystokinin Rattus norvegicus 85-88 3666030-1 1987 Systemic administration of the active, sulfated form of cholecystokinin-octapeptide (CCK-8S), at a dose known to inhibit dopamine (DA) release, significantly reduced the latency to ejaculate and number of intromissions preceding ejaculation in sexually active male rats. Dopamine 131-133 cholecystokinin Rattus norvegicus 85-88 3666030-5 1987 These data suggest that CCK-8S and apomorphine may reduce the ejaculation threshold in sexually active male rats by inhibition of DA release via two different mechanisms of action. Dopamine 130-132 cholecystokinin Rattus norvegicus 24-27 20488104-4 1984 CCK injected directly into the nucleus accumbens potentiated apomorphine-induced stereotypy and dopamine-induced hyperlocomotion. Dopamine 96-104 cholecystokinin Rattus norvegicus 0-3 3760947-1 1986 Cholecystokinin (CCK)-like peptides when administered intravenously produce 2 distinct actions on the single-unit activity of mesencephalic dopamine (DA) neurons in the rat: an excitatory action and a potentiation of the inhibitory effects of DA agonists. Dopamine 140-148 cholecystokinin Rattus norvegicus 0-15 3760947-1 1986 Cholecystokinin (CCK)-like peptides when administered intravenously produce 2 distinct actions on the single-unit activity of mesencephalic dopamine (DA) neurons in the rat: an excitatory action and a potentiation of the inhibitory effects of DA agonists. Dopamine 140-148 cholecystokinin Rattus norvegicus 17-20 3760947-1 1986 Cholecystokinin (CCK)-like peptides when administered intravenously produce 2 distinct actions on the single-unit activity of mesencephalic dopamine (DA) neurons in the rat: an excitatory action and a potentiation of the inhibitory effects of DA agonists. Dopamine 150-152 cholecystokinin Rattus norvegicus 0-15 3760947-1 1986 Cholecystokinin (CCK)-like peptides when administered intravenously produce 2 distinct actions on the single-unit activity of mesencephalic dopamine (DA) neurons in the rat: an excitatory action and a potentiation of the inhibitory effects of DA agonists. Dopamine 150-152 cholecystokinin Rattus norvegicus 17-20 3760947-2 1986 The ability of several CCK fragments that have been shown to bind selectively to the peripheral and/or the central CCK-binding sites were examined for their ability to induce either excitation or a potentiation of DA. Dopamine 214-216 cholecystokinin Rattus norvegicus 23-26 3760947-6 1986 Thus, CCK-like peptides that have been shown to bind to the high-affinity CCK binding site in brain potentiated the effects of DA. Dopamine 127-129 cholecystokinin Rattus norvegicus 6-9 3760947-6 1986 Thus, CCK-like peptides that have been shown to bind to the high-affinity CCK binding site in brain potentiated the effects of DA. Dopamine 127-129 cholecystokinin Rattus norvegicus 74-77 3958963-0 1986 Cholecystokinin octapeptides alter the release of endogenous dopamine from the rat nucleus accumbens in vitro. Dopamine 61-69 cholecystokinin Rattus norvegicus 0-15 3958963-1 1986 Sulfated cholecystokinin octapeptide (CCK-8S) has been reported to be extensively colocalized with dopamine in the posterior, but not the anterior, portion of the nucleus accumbens (NAc). Dopamine 99-107 cholecystokinin Rattus norvegicus 9-24 4045551-9 1985 Our results suggest that CCK acts to modulate the release of DA within the NAc in vivo in a complex manner, as it appears that the action of CCK depends not only on the concentration tested but also on the excitation state of the tissue during the testing period. Dopamine 61-63 cholecystokinin Rattus norvegicus 25-28 4045551-9 1985 Our results suggest that CCK acts to modulate the release of DA within the NAc in vivo in a complex manner, as it appears that the action of CCK depends not only on the concentration tested but also on the excitation state of the tissue during the testing period. Dopamine 61-63 cholecystokinin Rattus norvegicus 141-144 3855358-2 1985 Brain phenolsulfotransferase (PST) is involved in the sulfation of simple phenols like dopamine and of precursors of biologically active peptides like cholecystokinin octapeptide (CCK-8). Dopamine 87-95 cholecystokinin Rattus norvegicus 180-183 2417173-1 1985 Cholecystokinin (CCK), enkephalin, neurotensin (NT), substance P (SP) and substance K (SK) are five neuropeptides that exist in neuronal perikarya or fibers in the vicinity of the A10 dopamine neurons in the ventromedial mesencephalon. Dopamine 184-192 cholecystokinin Rattus norvegicus 0-15 3561887-1 1987 The hyperactivity induced by injection of the dopamine (DA) agonist apomorphine into the nucleus accumbens of rats was dose dependently inhibited by intra-accumbal pretreatment with cholecystokinin (CCK-8) (ED50, 0.34 ng). Dopamine 46-54 cholecystokinin Rattus norvegicus 182-197 3561887-1 1987 The hyperactivity induced by injection of the dopamine (DA) agonist apomorphine into the nucleus accumbens of rats was dose dependently inhibited by intra-accumbal pretreatment with cholecystokinin (CCK-8) (ED50, 0.34 ng). Dopamine 56-58 cholecystokinin Rattus norvegicus 182-197 20501122-8 1987 In nucleus accumbens, the CCK binding sites were concentrated in the anterior portion of the nucleus, whereas very low densities were observed within medial posterior nucleus accumbens, where injection of CCK has been shown to potentiate dopamine-induced hyperlocomotion. Dopamine 238-246 cholecystokinin Rattus norvegicus 26-29 20501122-8 1987 In nucleus accumbens, the CCK binding sites were concentrated in the anterior portion of the nucleus, whereas very low densities were observed within medial posterior nucleus accumbens, where injection of CCK has been shown to potentiate dopamine-induced hyperlocomotion. Dopamine 238-246 cholecystokinin Rattus norvegicus 205-208 20501123-1 1987 By means of intracerebral microdialysis effects of cholecystokinin peptides and neurotensin administered via the microdialysis probe have been studied on dopamine release and metabolism in the nucleus accumbens and neostriatum of the halothane anaesthetized male rat. Dopamine 154-162 cholecystokinin Rattus norvegicus 51-66 20501123-5 1987 accumbens CCK-8 (10 and 100 ?M), CCK-33 (100 ?M) but not CCK-4 (10 and 100 ?M) increased the levels of DA in the perfusate without increasing the extracellular levels of DOPAC and HVA. Dopamine 103-105 cholecystokinin Rattus norvegicus 33-36 20501123-5 1987 accumbens CCK-8 (10 and 100 ?M), CCK-33 (100 ?M) but not CCK-4 (10 and 100 ?M) increased the levels of DA in the perfusate without increasing the extracellular levels of DOPAC and HVA. Dopamine 103-105 cholecystokinin Rattus norvegicus 33-36 3108924-1 1987 Cholecystokinin octapeptide (CCK-8) is prevalent as a co-transmitter in the mesolimbic dopamine pathway. Dopamine 87-95 cholecystokinin Rattus norvegicus 0-15 3708329-6 1986 The data suggests that whereas it is difficult to observe any effects of exogenous dopamine agonists or antagonists on evoked CCK release, endogenously released dopamine appears to interact with D2-receptors to suppress evoked CCK release from rat striatal slices. Dopamine 161-169 cholecystokinin Rattus norvegicus 227-230 3012602-1 1986 The existence of the neuropeptide cholecystokinin (CCK) within a subpopulation of central dopamine (DA) neurons has led to speculations that the peptide may serve as an endogenous modulator of DA functions. Dopamine 90-98 cholecystokinin Rattus norvegicus 51-54 3012602-1 1986 The existence of the neuropeptide cholecystokinin (CCK) within a subpopulation of central dopamine (DA) neurons has led to speculations that the peptide may serve as an endogenous modulator of DA functions. Dopamine 100-102 cholecystokinin Rattus norvegicus 51-54 3012602-2 1986 To test this possibility, the present study examined the pharmacological action of CCK-8 by comparing its effects on DA-mediated circling behavior with those of a typical (haloperidol; HAL) and an atypical (clozapine; CLZ) dopamine antagonist neuroleptic drug. Dopamine 117-119 cholecystokinin Rattus norvegicus 83-86 4005562-1 1985 Sulfated cholecystokinin octapeptide (CCK) potentiates dopamine-induced hyperlocomotion in the nucleus accumbens of the rat. Dopamine 55-63 cholecystokinin Rattus norvegicus 38-41 4005562-3 1985 Seven sites within the nucleus accumbens were cannulated and tested for the ability of CCK to enhance the behavioral effects of DA. Dopamine 128-130 cholecystokinin Rattus norvegicus 87-90 2993947-4 1985 Cholecystokinin appreciably inhibited the circulation of serotonin and dopamine in the brain structures in comparison with physiological saline solution. Dopamine 71-79 cholecystokinin Rattus norvegicus 0-15 3991366-1 1985 Cholecystokinin octapeptide (CCK-8) or cholecystokinin tetrapeptide (CCK-4) were bilaterally injected into the areas where dopamine (DA) terminals and receptors have been detected; nucleus accumbens (NA), nucleus caudatus (NC), medial profrontal cortex (MPC), or prefrontal cortex (PC). Dopamine 123-131 cholecystokinin Rattus norvegicus 0-15 4080721-5 1985 DA also reversed CCK-induced excitation, presumably by its hyperpolarizing actions. Dopamine 0-2 cholecystokinin Rattus norvegicus 17-20 6324955-0 1984 In vivo release of dopamine in the nucleus accumbens of the rat: modulation by cholecystokinin. Dopamine 19-27 cholecystokinin Rattus norvegicus 79-94 6324955-2 1984 We also demonstrated that the sulphated form of cholecystokinin octapeptide, but not the unsulphated form, suppressed this stimulated release of dopamine in a concentration-dependent manner. Dopamine 145-153 cholecystokinin Rattus norvegicus 48-63 6324955-3 1984 This suggests that cholecystokinin may act as a functional antagonist to dopamine within this structure. Dopamine 73-81 cholecystokinin Rattus norvegicus 19-34 6717857-1 1984 We have investigated the effect of the cholecystokinin (CCK) analogue, caerulein, in the nucleus accumbens on dopamine (DA) release and locomotor activity. Dopamine 110-118 cholecystokinin Rattus norvegicus 39-54 6717857-1 1984 We have investigated the effect of the cholecystokinin (CCK) analogue, caerulein, in the nucleus accumbens on dopamine (DA) release and locomotor activity. Dopamine 110-118 cholecystokinin Rattus norvegicus 56-59 6717857-1 1984 We have investigated the effect of the cholecystokinin (CCK) analogue, caerulein, in the nucleus accumbens on dopamine (DA) release and locomotor activity. Dopamine 120-122 cholecystokinin Rattus norvegicus 56-59 20488104-8 1984 These data suggest that CCK acts as a modulator of dopamine, increasing neuronal responses to dopaminergic agonists. Dopamine 51-59 cholecystokinin Rattus norvegicus 24-27 20488104-9 1984 The potentiation of dopamine by CCK may be specific to the mesolimbic neurons, where CCK and DA co-exist in the rat. Dopamine 20-28 cholecystokinin Rattus norvegicus 32-35 20488104-9 1984 The potentiation of dopamine by CCK may be specific to the mesolimbic neurons, where CCK and DA co-exist in the rat. Dopamine 20-28 cholecystokinin Rattus norvegicus 85-88 6828873-1 1983 Extracellular single-unit recording techniques were used to test the ability of proglumide to block cholecystokinin-induced excitation of rat midbrain dopaminergic neurons and dopamine-sensitive prefrontal cortex cells. Dopamine 151-159 cholecystokinin Rattus norvegicus 100-115 6318205-0 1983 CCK-8 modulation of mesolimbic dopamine: antagonism of amphetamine-stimulated behaviors. Dopamine 31-39 cholecystokinin Rattus norvegicus 0-3 6318205-7 1983 These results suggest a modulation of dopaminergically-mediated behavior by (sulfated) CCK-8 at the cell body region and terminal fields of the mesolimbic (A10) dopamine system. Dopamine 38-46 cholecystokinin Rattus norvegicus 87-90 7173435-0 1982 [Intracerebroventricular administration of cholecystokinin inhibits the dopamine- and serotoninergic systems of the brain]. Dopamine 72-80 cholecystokinin Rattus norvegicus 43-58 7173435-2 1982 Cholecystokinin suppressing markedly dopamine and serotonin turnover in various brain structures, completely blocked the behavioral effects of amphetamine (2.5 mg/kg) and 5-hydroxytryptophan (150 mg/kg). Dopamine 37-45 cholecystokinin Rattus norvegicus 0-15 7173435-3 1982 The data obtained suggest that cholecystokinin suppresses presynaptic dopamine- and serotoninergic mechanisms but enhances the sensitivity of postsynaptic receptors of these systems. Dopamine 70-78 cholecystokinin Rattus norvegicus 31-46 24732637-1 2014 BACKGROUND: The neuropeptide cholecystokinin (CCK) has been implicated in the neurobiology of anxiety and panic disorders, as well as in dopamine-related behaviours. Dopamine 137-145 cholecystokinin Rattus norvegicus 46-49 7315376-2 1981 CCK antiserum decreased the DA and NE contents in the hypothalamus, mesencephalon, amygdala and septum, while it increased the DA content and decreased the NE content of the striatum. Dopamine 28-30 cholecystokinin Rattus norvegicus 0-3 7126854-0 1982 [Effect of cholecystokinin on dopamine metabolism in the rat brain]. Dopamine 30-38 cholecystokinin Rattus norvegicus 11-26 7126854-1 1982 The effect of sulfated octapeptide of cholecystokinin (CCK) on dopamine turnover was examined in different parts of the rat brain. Dopamine 63-71 cholecystokinin Rattus norvegicus 38-53 7126854-1 1982 The effect of sulfated octapeptide of cholecystokinin (CCK) on dopamine turnover was examined in different parts of the rat brain. Dopamine 63-71 cholecystokinin Rattus norvegicus 55-58 7126854-2 1982 It was demonstrated that CCK administered intrapeutoneally in doses of 5, 15 and 30 micrograms/kg significantly increased dopamine turnover in the amygdala, and nucleus accumbeus, without changing dopamine turnover in the midbrain, hypothalamus and striatum. Dopamine 122-130 cholecystokinin Rattus norvegicus 25-28 7126854-3 1982 The data suggest that variation in the activity of the mesolimbic dopamine system might be one of the mechanisms by which CCK regulates the animals behavior. Dopamine 66-74 cholecystokinin Rattus norvegicus 122-125 20487821-2 1981 Cholecystokinin octapeptide sulphate ester and the tyrosine-sulphate-methionine and tyrosine-sulphate-methionine-glycine fragments increased the dopamine and norepinephrine contents of the hypothalamus and mesencephalon. Dopamine 145-153 cholecystokinin Rattus norvegicus 0-15